Compare SLDB & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | MCB |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2017 |
| Metric | SLDB | MCB |
|---|---|---|
| Price | $8.70 | $90.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | $16.36 | ★ $98.67 |
| AVG Volume (30 Days) | ★ 751.6K | 72.5K |
| Earning Date | 05-12-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | ★ 34.97 | 11.64 |
| EPS | N/A | ★ 4.40 |
| Revenue | $8,094,000.00 | ★ $11,053,000.00 |
| Revenue This Year | N/A | $37.22 |
| Revenue Next Year | N/A | $14.75 |
| P/E Ratio | ★ N/A | $20.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.79 | $64.66 |
| 52 Week High | $11.45 | $102.04 |
| Indicator | SLDB | MCB |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 43.96 |
| Support Level | $6.25 | $89.82 |
| Resistance Level | $11.45 | $93.56 |
| Average True Range (ATR) | 0.42 | 1.73 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 14.18 | 37.68 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.